Cargando…
Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly
Genexol-PM, produced by Samyang Company (Korea) is an excellent preparation of paclitaxel (PTX) for clinical cancer treatment. However, it cannot resolve the issue of multidrug resistance (MDR)—a significant problem in the administration of PTX to cancer patients. To increase the efficacy of Genexol...
Autores principales: | Fan, Zhuoyang, Chen, Cheng, Pang, Xiaoying, Yu, Zhou, Qi, Yang, Chen, Xinyi, Liang, Huihui, Fang, Xiaoling, Sha, Xianyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382049/ https://www.ncbi.nlm.nih.gov/pubmed/25831130 http://dx.doi.org/10.1371/journal.pone.0120129 |
Ejemplares similares
-
Correction: Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly
Publicado: (2015) -
Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation
por: Chen, Yanzuo, et al.
Publicado: (2013) -
Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study
por: Nam, So Hyun, et al.
Publicado: (2023) -
TPGS/Phospholipids Mixed Micelles for Delivery of Icariside II to Multidrug-Resistant Breast Cancer
por: Song, Jie, et al.
Publicado: (2015) -
Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer
por: Saxena, Vipin, et al.
Publicado: (2012)